


Curriculum Vitae

Personal Information			
Title	Prof		
Name	Peter Gibson		
Degree	MD		
Country	Australia		
Affiliation	Monash University		
E-mail	peter.gibson(at)monash.edu		
Educational Background			
INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
Monash University, Melbourne	M.B., B.S. (Hons.)	1975	
Royal Australasian College of Physicians	F.R.A.C.P.	1984	Gastroenterology
Monash University, Melbourne	M.D.	1985	Gastroenterology & immunology
Professional Career			
<p>Peter Gibson is Professor of Gastroenterology at the Central Clinical School, Monash University. He was formerly Professor-Director of Gastroenterology at Alfred Health and, prior to that, Professor of Medicine and the founding Head of the Eastern Health Clinical School. He has published more than 450 papers, and was the recipient of the Distinguished Research Award from the Gastroenterological Society of Australia in 2010 and the Web of Science Highly Cited Researchers Awards in 2020-2023.</p>			
Research Field			
<p>From a background of research in epithelial cell biology, he directs a program of translational research with major foci being in inflammatory bowel disease and irritable bowel syndrome. Major foci of his work include the use of non-pharmacological therapy, especially diet, to control gut symptoms and influence outcomes in chronic intestinal conditions, and the optimisation of clinical management in inflammatory bowel disease.</p>			
Main Scientific Publications			
<p>4 Main Areas:</p> <ol style="list-style-type: none"> Dietary management of chronic intestinal conditions: <ul style="list-style-type: none"> Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. <i>Gastroenterology</i> 2014;146:67-75. Biesiekierski JR, Peters SL, Newnham ED, Rosella O, Muir JG, Gibson PR. No effects of gluten in patients with self-reported non-celiac gluten sensitivity following dietary reduction of fermentable, poorly-absorbed, short-chain carbohydrates. <i>Gastroenterology</i> 2013;145:320-8. Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. <i>Nat Rev Gastroenterol Hepatol.</i>2022;19:652-669. The importance of psychological, cognitive and behavioural health in chronic intestinal conditions. <ul style="list-style-type: none"> Peters SL, Yao CK, Philpott H, Yelland GW, Muir JG, Gibson PR. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. <i>Aliment Pharmacol Ther.</i> 2016;44:447-59. 			



- Peters SL, Gibson PR, Halmos EP. Smartphone app-delivered gut-directed hypnotherapy improves symptoms of self-reported irritable bowel syndrome: A retrospective evaluation. *Neurogastroenterol Motil.* 2023;Jan 20:e14533.

3. Swallowable telemetric technology:

- Kalantar-zadeh K, Berean KJ, Ha N, Chrimes AF, Xu K, Grando D, Ou JZ, Pillai N, Campbell JL, Brkljača R, Taylor KM, Burgell RE, Chu K, Yao CK, Ward SA, McSweeney CS, Muir JG, Gibson PR. First in-Human Pilot Trial of Ingestible Electronic based Gas Sensing Capsules: Dietary Modulation along the Gut. *Nature Electronics* 2018;1:79-87
- So D, Yao CK, Gill PA, Thwaites PA, Ardalan ZS, McSweeney CS, Denman SE, Chrimes AF, Muir JG, Berean KJ, Kalantar-Zadeh K, Gibson PR. Detection of changes in regional colonic fermentation in response to supplementing a low FODMAP diet with dietary fibres by hydrogen concentrations, but not by luminal pH. *Aliment Pharmacol Ther.* 2023;58:417-428. PMID: 37386938.

4. Optimising therapies in patients with inflammatory bowel disease (IBD):

- Friedman AB, Asthana A, Knowles SR, Robbins A, Gibson PR. Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2021;54:652-666.
- Mogilevski T, Rosella S, Aziz Q, Gibson PR. Transcutaneous vagal nerve stimulation protects against stress-induced intestinal barrier dysfunction in healthy adults. *Neurogastroenterol Motil.* 2022 Oct;34(10):e14382.